Clinical research
The antibody is still being evaluated in clinical studies, with a large-scale Phase III trial expected to wrap in the second half of 2022.
The company said it has decided to close the study’s open-label and maintenance portions given the inability to satisfy endpoint goals.
The study will also investigate the oral combination with PD-1 inhibitor pembrolizumab in EBV+ metastatic nasopharyngeal carcinoma (RM-NPC).
Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
The drug is a nucleoside reverse transcriptase translocation inhibitor, with the results presented at the virtual 11th International AIDS Society Conference on HIV Science.
The recent survival results of Masitinib will help (ALS) patients to live longer. AB Science has successfully established the sweet spot for masitinib in ALS.
Genentech’s Hemlibra showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
The firm would be moving forward to Phase III for the treatment of hypertrophic cardiomyopathy, which is expected to commence before the end of 2021.
The CDC Advisory Committee on Immunization Practices is planning a meeting in October to recommend the vaccine’s use in adults.
PRESS RELEASES